Acurx shares surge 12.2% intraday on forecasts of $20M profit in 2028 and breakeven timeline.

Acurx Pharmaceuticals (NASDAQ:ACXP) surged 12.20% intraday as analysts projected the company will breakeven by 2028, with anticipated $20M in profits following a 2027 loss. The forecast highlights a 48% annual growth rate, which, while optimistic, aligns with investor optimism about the company’s medium-term turnaround. Additionally, Acurx’s debt-free balance sheet—a rarity for a loss-making biotech—reduces financial risk, further supporting positive sentiment. These factors collectively drove the intraday rally.